AR054094A1 - Tratamientos de cancer - Google Patents

Tratamientos de cancer

Info

Publication number
AR054094A1
AR054094A1 ARP050104642A ARP050104642A AR054094A1 AR 054094 A1 AR054094 A1 AR 054094A1 AR P050104642 A ARP050104642 A AR P050104642A AR P050104642 A ARP050104642 A AR P050104642A AR 054094 A1 AR054094 A1 AR 054094A1
Authority
AR
Argentina
Prior art keywords
methods
cancer treatments
cancer cells
treatments
bendamustine
Prior art date
Application number
ARP050104642A
Other languages
English (en)
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of AR054094A1 publication Critical patent/AR054094A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen métodos y composiciones para tratar cánceres caracterizados por células cancerosas resistentes a la muerte. En general, tales métodos involucran la administracion de una cantidad terapéuticamente efectiva de un compuesto (Bendamustina) que induce la catástrofe mitotica en algunas, preferentemente en la mayoría o en todas, las células cancerosas. Se proveen también métodos para valorar la eficacia de tales tratamientos.
ARP050104642A 2004-11-05 2005-11-04 Tratamientos de cancer AR054094A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62519304P 2004-11-05 2004-11-05
US66022605P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
AR054094A1 true AR054094A1 (es) 2007-06-06

Family

ID=36588320

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104642A AR054094A1 (es) 2004-11-05 2005-11-04 Tratamientos de cancer

Country Status (12)

Country Link
US (2) US20060128777A1 (es)
EP (1) EP1814544A4 (es)
JP (1) JP2008519047A (es)
CN (1) CN101933923A (es)
AR (1) AR054094A1 (es)
AU (1) AU2005317047A1 (es)
CA (1) CA2585659A1 (es)
CL (1) CL2009001721A1 (es)
MX (1) MX2007005361A (es)
NO (1) NO20072654L (es)
TW (1) TW200621240A (es)
WO (1) WO2006065392A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542445A (en) 2003-04-07 2008-03-28 Pharmacyclics Inc Hydroxamates as therapeutic agents
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US20090075967A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ceftriaxone
US20090082416A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN102056607B (zh) * 2008-04-17 2014-07-30 约翰·霍普金斯大学 On01910.na促进在抗药性肿瘤中化学治疗剂的活性
WO2010036702A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
DK2367542T3 (da) * 2008-12-03 2014-03-10 Astellas Deutschland Gmbh Orale doseringsformer af bendamustin
JP5654498B2 (ja) * 2009-02-25 2015-01-14 スプラテック ファーマ インコーポレイテッド ベンダムスチン環状多糖組成物
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
EP2424506A1 (en) * 2009-04-28 2012-03-07 Cephalon, Inc. Oral formulations of bendamustine
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
HUE031208T2 (hu) 2010-01-28 2017-07-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
MX2012013872A (es) * 2010-06-02 2013-04-03 Astellas Deutschland Gmbh Formas de dosificacion oral de bendamustina.
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
SG10201606785UA (en) 2011-08-16 2016-10-28 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
CN103917231B (zh) * 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
ES2613838T3 (es) 2011-09-26 2017-05-26 Fresenius Kabi Oncology Ltd Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina
RS65177B1 (sr) 2012-03-20 2024-03-29 Eagle Pharmaceuticals Inc Formulacije bendamustina
RS64137B1 (sr) 2012-03-20 2023-05-31 Eagle Pharmaceuticals Inc Tečne kompozicije bendamustina za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za primenu
US8927516B2 (en) * 2012-03-29 2015-01-06 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
US10220051B2 (en) 2012-03-29 2019-03-05 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
TWI649081B (zh) 2013-08-02 2019-02-01 製藥公司 治療固態腫瘤之方法
US20150087681A1 (en) * 2013-09-25 2015-03-26 Pranav Patel Bendamustine HCL Stable Lyophilized Formulations
CA2925922C (en) 2013-09-30 2023-03-21 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Inhibition of thymine dna glycosylase in the treatment of cancer
CA2941632C (en) * 2014-03-13 2023-10-24 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
DE69329503T2 (de) * 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ATE187071T1 (de) * 1993-10-27 1999-12-15 Upjohn Co Stabilisiertes prostaglandin e1
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
GB9524334D0 (en) * 1995-11-28 1996-01-31 Philips Electronics Nv Mos transistor
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
ES2255287T3 (es) * 1998-07-09 2006-06-16 Cephalon, Inc. Composiciones para el tratamiento de la leucemia linfocitica cronica.
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
PL362979A1 (en) * 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
CA2431322A1 (en) * 2000-12-11 2002-06-20 Eiji Nara Medicinal compositions having improved absorbability
ATE428372T1 (de) * 2001-10-15 2009-05-15 Hemoteq Ag Beschichtung von stents zur verhinderung von restenose
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
ES2321082T3 (es) * 2002-05-09 2009-06-02 Hemoteq Ag Productos medicos que comprenden un revestimiento hemocompatible, produccion y uso de los mismos.
US20040096436A1 (en) * 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
US6966329B2 (en) * 2003-01-27 2005-11-22 Hydraforce, Inc. Proportional pilot-operated flow control valve
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
CA2516191A1 (en) * 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers

Also Published As

Publication number Publication date
CL2009001721A1 (es) 2010-02-19
EP1814544A4 (en) 2009-12-02
WO2006065392A2 (en) 2006-06-22
EP1814544A2 (en) 2007-08-08
US20060128777A1 (en) 2006-06-15
WO2006065392A8 (en) 2007-03-01
US20090209606A1 (en) 2009-08-20
NO20072654L (no) 2007-07-25
WO2006065392A3 (en) 2006-12-21
AU2005317047A1 (en) 2006-06-22
JP2008519047A (ja) 2008-06-05
MX2007005361A (es) 2008-01-11
CN101933923A (zh) 2011-01-05
CA2585659A1 (en) 2006-06-22
TW200621240A (en) 2006-07-01

Similar Documents

Publication Publication Date Title
AR054094A1 (es) Tratamientos de cancer
UY28287A1 (es) Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
UY27712A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimientos de fabricación y utilización
NO20065368L (no) Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin
AR048502A1 (es) Sinergia terapeutica de compuestos anti-cancer
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
ECSP088218A (es) Bencimidazoles sustituidos como inhibidores de cinasa
BRPI0517135A (pt) composições e métodos para tratar doenças neoplásticas
AR056801A1 (es) Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
PA8680701A1 (es) Derivados de oxindol
AR054566A1 (es) Tratamientoombinado de los tumores que expresan el her
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
IL186960A0 (en) Methods of suppressing uv light-induced skin carcinogenesis
WO2009032057A3 (en) Method for the selective therapy of disease
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.
UY31325A1 (es) Composiciones y métodos para tratar enfermedades y trastornos inmunologicos e inflamatorios

Legal Events

Date Code Title Description
FB Suspension of granting procedure